Business
OXB expands US footprint with acquisition of commercial-scale viral vector facility in North Carolina
OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s previously announced strategy to add US GMP capacity across drug substance and fill-finish to meet growing client demand Strengthens OXB’s global CDMO network and enhances service offering for existing and prospective clientsSupports existing near and medium-term financial guidance Oxford, UK – 7 October 2025: OXB (LSE: OXB), a global quality and innovation-l
About this update from Oxford Biomedica Plc
[{"type":"image","alt":"OXB","displaySize":"","headline":null,"caption":"OXB","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":159,"url":"https://media.zenfs.com/en/globenewswire.com/c14d9d68668513a9042681f5e1f388c2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fa8vdAQ1u36jC9pq9QpcgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c14d9d68668513a9042681f5e1f388c2","width":300,"height":159}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility ","length":119,"tagName":"p"}]},{"val":[{"type":"text","content":"In line with OXB’s previously announced strategy to add US GMP capacity across drug substance and fill-finish to meet growing client demand ","length":139,"tagName":"p"}]},{"val":[{"type":"text","content":"Strengthens OXB’s global CDMO network and enhances service offering for existing and prospective clients","length":104,"tagName":"p"}]},{"val":[{"type":"text","content":"Supports existing near and medium-term financial guidance","length":57,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":419,"olType":false},{"type":"text","content":"Oxford, UK – 7 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that it has signed and closed an asset purchase transaction to acquire a custom-built, state-of-the-art cell and gene therapy viral vector manufacturing facility in North Carolina from RTP Operating, LLC, a subsidiary of National Resilience Holdco, Inc. (Resilience).","length":397,"tagName":"p"},{"type":"text","content":"Commercial-scale GMP capacity in the US to meet demand from existing and new clientsThe acquisition expands OXB’s viral vector manufacturing capabilities in the US up to commercial-scale, increasing GMP capacity and enhancing services to clients across North America. The FDA approved facility in Durham, North Carolina adds scalable vector manufacturing capabilities and end-to-end services across drug substance and fill-finish. This acquisition enables OXB to support late-stage programmes and commercial launches from the US for new and existing clients worldwide, particularly in the adeno-associated virus (AAV) field. By leveraging an esta...